МОЛЕКУЛЯРНЫЕ БИОМАРКЕРЫ В ДИАГНОСТИКЕ, СТРАТИФИКАЦИИ РИСКА И ПРОГНОЗИРОВАНИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

Классические проявления застойной сердечной недостаточности имеют недостаточно высокую чувствительность и специфичность, что приводит к поздней диагностике и ухудшению прогноза заболевания. Концепция молекулярных биомаркеров получила широкое развитие в последнее десятилетие. К настоящему времени описан ряд биомаркеров, отражающих различные патофизиологические процессы, формирующие звенья патогенеза хронической сердечной недостаточности. Они являются надежным, безопасным и объективным средством диагностики и стратификации риска неблагоприятных событий, дополняющим клинические и инструментальные данные и отражающим особенности механизмов развития и прогрессирования заболевания у конкретного пациента. Данный обзор посвящен обобщению имеющихся доказательных данных о роли биомаркеров в диагностике и стратификации риска.

1. Dunlay S, Pereira N, Kushwaha S. Contemporary strategies in the diagnosis and management of heart failure. Mayo Clin Proc. 2014; 89(5): 662-76. doi: 10.1016/j.mayocp.2014.01.004

2. Gyamdzhan K, Drapkina O. Galectin-3: clinical and prognostic value in patients with chronic heart failure. Zhurnal Serdechnaya nedostatochnost’ 2014; 82 (1): 51-5 Russian (Гямджан К.А., Драпкина О.М., Максимов М.Л. Галектин-3: клиническая и прогностическая ценность определения у пациентов с ХСН. Журнал Сердечная Недостаточность. 2014; 82 (1): 51-5).

3. Yancy C, Jessup M, Bozkurt B, et al. Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240-e327. doi: 10.1016/j.jacc.2013.05.019.

4. McMurray J, Adamopoulos S, Anker S, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012; 33(14): 1787-847. doi: 10.1093/eurheartj/ehs104.

5. D’Alessandro R, Masarone D, Buono A, et al. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. Future Cardiology. 2013; 9(4): 519-34. doi:10.2217/fca.13.32.

6. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. The American Journal of Medicine. 2001; 111(4): 274-9. doi:10.1016/s0002-9343(01)00841-5.

7. Maisel A, Mueller C, Adams K, et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-39. doi: 10.1016/j.ejheart.2008.07.014.

8. Costello-Boerrigter L, Boerrigter G, Redfield M, et al. Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community. Journal of the American College of Cardiology. 2006; 47(2): 345-53. doi:10.1016/j.jacc.2005.09.025.

9. de Lemos J, McGuire D, Khera A, et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 2009; 157: 746-53. doi: 10.1016/j.ahj.2008.12.017.

10. Goetze J, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006; 27: 3004-10.

11. Ng L, Loke I, Davies J, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. Journal of the American College of Cardiology. 2005; 45(7): 1043-50.

12. Campbell SM, Fuat A, Summerton N, et al. Diagnostic triage and the role of natriuretic peptide testing and echocardiography for suspected heart failure: an appropriateness ratings evaluation by UK GPs. British Journal of General Practice [Internet]. Royal College of General Practitioners; 2011 Jul 1; 61(588): 427-35. http://dx.doi.org/10.3399/bjgp11x583218

13. Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart [Internet]. BMJ; 2011 Apr 8; 97(12): 959-63. http://dx.doi.org/10.1136/hrt.2010.220426

14. Kelder JC, Cramer MJ, Verweij WM, et al. Clinical Utility of Three B-Type Natriuretic Peptide Assays for the Initial Diagnostic Assessment of New Slow-Onset Heart Failure. Journal of Cardiac Failure [Internet]. Elsevier BV; 2011 Sep; 17(9): 729-34. http://dx.doi.org/10.1016/j.cardfail.2011.04.013

15. Mareev V, Ageev V, Arutunov G, et al. National guidelines on diagnosis and treatment of chronic heart failure. Heart Failure 2013; 7(81): 1-94. Russian (Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность 2013; 7(81): 1-94).

16. Moertl D, Berger R, Struck J, et al. Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure. Journal of the American College of Cardiology [Internet]. Elsevier BV; 2009 May; 53(19): 1783-90. http://dx.doi.org/10.1016/j.jacc.2009.01.057

17. Shah R, Truong Q, Gaggin H, et al. Mid-regional pro-atrial natriuretic peptide and proadrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. European Heart Journal. 2012; 33(17): 2197-205. doi:10.1093/eurheartj/ehs136.

18. Thygesen K, Alpert J, White H. Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology. 2007; 50(22): 2173-95. doi:10.1016/j.jacc.2007.09.011.

19. Dieplinger B, Gegenhuber A, Haltmayer M, et al. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009; 95(18): 1508-13. doi:10.1136/hrt.2009.170696.

20. Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea. Journal of the American College of Cardiology [Internet]. Elsevier BV; 2007 Aug; 50(7): 607-13. http://dx.doi.org/10.1016/j.jacc.2007.05.014

21. Aldous S, Richards A, Troughton R, et al. ST2 Has Diagnostic and Prognostic Utility for All-Cause Mortality and Heart Failure in Patients Presenting to the Emergency Department With Chest Pain. Journal of Cardiac Failure. 2012; 18(4): 304-10. doi:10.1016/j.cardfail.2012.01.008.

22. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351-60. http://dx.doi.org/10.1161/01.res.0000202805.73038.48

23. Kempf T, Wollert K. Growth-Differentiation Factor-15 in Heart Failure. Heart Failure Clinics. 2009; 5(4): 537-47. doi:10.1016/j.hfc.2009.04.006.

24. Baessler A, Strack C, Rousseva E, et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. European Journal of Heart Failure. 2012; 14(11): 1240-8. doi:10.1093/eurjhf/hfs116.

25. Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. European Journal of Heart Failure. 2010; 12(12): 1309-16. doi:10.1093/eurjhf/hfq151.

26. Doust J. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005; 330(7492): 625-0. doi:10.1136/bmj.330.7492.625.

27. Cohen-Solal A, Logeart D, Huang B, et al. Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure. Journal of the American College of Cardiology. 2009; 53(25): 2343-8. doi:10.1016/j.jacc.2009.02.058.

28. Kociol R, Horton J, Fonarow G, et al. Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims. Circulation: Heart Failure. 2011; 4(5): 628-36. doi:10.1161/circheartfailure.111.962290.

29. Miller W, Hartman K, Grill D, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart. 2011; 98(5): 389-94. doi:10.1136/heartjnl-2011-300823.

30. von Haehling S, Jankowska E, Morgenthaler N, et al. Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2007; 50(20): 1973-80. doi:10.1016/j.jacc.2007.08.012.

31. Lala R, Puschita M, Darabantiu D, et al. Galectin-3 in heart failure pathology — “another brick in the wall”? Acta Cardiol 2015; 70(3): 323-31.

32. de Boer R, Lok D, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine. 2011; 43(1): 60-8. doi:10.3109/07853890.2010.538080.

33. Lok D, Van Der Meer P, de la Porte P, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010; 99(5): 323-8. doi:10.1007/s00392-010-0125-y.

34. Lok D, Lok S, Bruggink-André de la Porte P, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2012; 102(2): 103-10. doi:10.1007/s00392-012-0500-y.

35. van der Velde A, Gullestad L, Ueland T, et al. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH. Circulation: Heart Failure. 2013; 6(2): 219-26. doi:10.1161/circheartfailure.112.000129.

36. Pascual-Figal D, Ordoñez-Llanos J, Tornel P, et al. Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology. 2009; 54(23): 2174-9. doi:10.1016/j.jacc.2009.07.041.

37. Broch K, Ueland T, Nymo S, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure. 2012; 14(3): 268-77. doi:10.1093/eurjhf/hfs006.

38. Rehman S, Mueller T, Januzzi J. Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. Journal of the American College of Cardiology. 2008; 52(18): 1458-65. doi:10.1016/j.jacc.2008.07.042.

39. Piper S, Sherwood R, Amin-Youssef G, et al. Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. International Journal of Cardiology. 2015; 178: 284-91. doi:10.1016/j.ijcard.2014.11.097.

40. Bayes-Genis A, Pascual-Figal D, Januzzi J, et al. Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. Revista Española de Cardiología (English Edition). 2010; 63(10): 1171-8. doi:10.1016/s1885-5857(10)70231-0.

41. Schmitter D, Cotter G, Voors A. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 2014; 19: 369-81. doi 10.1007/s10741-013-9396-5

42. Masson S, Anand I, Favero C, et al. Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials. Circulation. 2011; 125(2): 280-8. doi:10.1161/circulationaha.111.044149.

43. de Antonio M, Lupon J, Galan A, et al. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. American Heart Journal. 2012; 163(5): 821-8. doi:10.1016/j.ahj.2012.03.004.

44. Kempf T, von Haehling S, Peter T, et al. Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. Journal of the American College of Cardiology. 2007; 50(11): 1054-60. doi:10.1016/j.jacc.2007.04.091.

45. Anand I, Kempf T, Rector T, et al. Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial. Circulation. 2010; 122(14): 1387-95. doi:10.1161/circulationaha.109.928846.

46. Ky B, French B, Levy W, et al. Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. Circulation: Heart Failure. 2012; 5(2): 183-90. doi:10.1161/circheartfailure.111.965020.

47. Bayes-Genis A, Richards A, Maisel A, et al. Multimarker Testing With ST2 in Chronic Heart Failure. The American Journal of Cardiology. 2015; 115(7): 76B-80B. doi:10.1016/j.amjcard.2015.01.045.

48. Lupón J, de Antonio M, Galán A, et al. Combined Use of the Novel Biomarkers HighSensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment. Mayo Clinic Proceedings. 2013; 88(3): 234-43. doi:10.1016/j.mayocp.2012.09.016.

49. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure. 2014; 2(3): 260-8. doi:10.1016/j.jchf.2013.12.004.

50. Gaggin H, Szymonifka J, Bhardwaj A. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail 2014; 2(1): 65-72. doi: 10.1016/j.jchf.2013.10.005.